九源基因(02566)绩后涨超7%，截至发稿，涨7.02%，报15.4港元，成交额1024.28万港元。 截至2025年6月30日，公司实现收入总额同比下降9.1%，期内溢利同比下降14.4%。上半年收入总额小 幅下滑主要受内外部因素综合影响。 消息面上，8月19日，九源基因发布截至2025年6月30日止6个月的中期业绩，该集团取得收益人民币 6.39亿元(单位下同)，同比下降9.05%；毛利5.25亿元，同比下降2.84%；母公司股东应占纯利9017.4万 元，同比下降14.4%；每股盈利0.37元。 本报告期内，公司骨科领域产品销量同比增长超过10%，医院渗透率持续提升。围绕公司全年经营目 标，以稳定现有市场和培育增量市场为着力点实施差异化商业政策，争取实现全年业务收入的平稳增 长。 ...

Core Viewpoint - Jiuyuan Gene (02566) experienced a stock price increase of over 7% following the release of its interim results, indicating market optimism despite a decline in financial performance [1] Financial Performance - For the six months ending June 30, 2025, Jiuyuan Gene reported revenue of RMB 639 million, a year-on-year decrease of 9.05% [1] - Gross profit was RMB 525 million, down 2.84% year-on-year [1] - Net profit attributable to shareholders was RMB 90.17 million, reflecting a decline of 14.4% compared to the previous year [1] - Earnings per share stood at RMB 0.37 [1] Market Dynamics - The overall revenue decline of 9.1% was attributed to a combination of internal and external factors [1] - Sales of orthopedic products increased by over 10% year-on-year, indicating growth in this segment [1] - The company is focusing on stabilizing existing markets and cultivating new ones through differentiated commercial policies to achieve steady annual revenue growth [1]